A Skeptical Take on Current Alzheimer’s Therapy: FDA’s Temple Says Problem Is Drugs, Not Endpoints
This article was originally published in RPM Report
Executive Summary
When it comes to Alzheimer’s Drug development, FDA’s Bob Temple firmly believes regulatory standards are not the problem. “You just need a drug that works.”